One of the most common cancers in males worldwide is prostate cancer, which calls for creative ways to improve patient outcomes and treatment effectiveness. Prostate cancer treatment has great promise; owing to personalized medicine, which is defined by the customization of medical care to each patient’s unique characteristics. This approach explores proteomic, genomic, and epigenomic profiling to identify distinct tumor features, allowing physicians to group patients according to their response levels to particular treatments. Targeted treatments, such as androgen receptor inhibitors and PARP inhibitors, have been made possible by recent advancements in biomarker discovery, such as the identification of genetic mutations and abnormalities linked to the advancement of prostate cancer. Additionally, further improvement of individualized treatment regimens is anticipated through the use of machine learning and artificial intelligence tools in the analysis of large datasets. This chapter comprises the application of personalized medicine in prostate cancer, with particular emphasis on recent developments, ongoing clinical studies, and the challenges associated with delivering customized treatments to a range of patient demographics. Finally, the avenues and possibilities of switching from a one-size-fits-all strategy to tailored ones by having the potential to momentously augment the quality of life and therapeutic benefits for patients with prostate cancer will be presented.